Meso Foundation Congratulates Dr. Krug on his New Position

Dr. Lee Krug

Dr. Lee KrugThe Mesothelioma Applied Research Foundation would like to congratulate Dr. Lee M. Krug on his new position with Bristol-Myers Squibb (BMS), which he will be starting in August. He will be joining BMS as the Immuno-oncology Disease Head for Thoracic and GI Malignancies.

Dr. Krug will be leaving his position as an Associate Attending Physician in the Division of Thoracic Oncology, Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York, New York.

“I promise to remain committed to the foundation and the search for the cure for mesothelioma,” said Dr. Krug.

Dr. Krug has investigated multimodality mesothelioma treatment approaches for patients with early stage malignant pleural mesothelioma. He led a multicenter U.S. trial of induction chemotherapy before extrapleural pneumonectomy, and he has a current study testing the feasibility of chemotherapy followed by pleural radiation. Dr. Krug also has a strong interest in novel therapeutics for patients with more advanced disease. He conducted a phase I trial with a WT-1 peptide vaccine, and he was awarded a grant from the Department of Defense to conduct a randomized phase II trial with this vaccine. He is also the principal investigator of an international, phase III trial of a histone deacetylase inhibitor, vorinostat. Dr. Krug led the committee for the National Comprehensive Cancer Network (NCCN) that established treatment guidelines for mesothelioma.

“Dr. Krug has an unwavering dedication to the mesothelioma field, and I am excited to see what new insight he will bring to the field with his new position at BMS,” stated Melinda Kotzian, Chief Executive Officer at the Meso Foundation.

We congratulate Dr. Krug and wish him the best in his new position.

Be the first to comment on "Meso Foundation Congratulates Dr. Krug on his New Position"

Leave a comment

Your email address will not be published.


*